Blood-clot drug from Bayer, J&J yields mixed midstage data

11/10/2008 | Reuters

Rivaroxaban, an anti-clotting drug from Bayer AG and Johnson & Johnson, failed to make a statistically significant difference in lowering risks of stroke, heart attack, severe recurrent chest pain and death compared with placebo in a midstage trial of patients with acute coronary syndrome. The companies plan to pursue late-stage development because overall data from the study "were persuasive enough," the lead researcher said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX